Pretax income is the income that a company earns before paying income taxes. Evoke Pharma's pretax income for the
three
months ended in Sep. 2024 was $-1.31 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-6.15 Mil.
Evoke Pharma's pretax margin was -49.43%.
During the past 13 years, Evoke Pharma's highest Pretax Margin was -71.33%. The lowest was -57195.65%. And the median was -427.74%.
Evoke Pharma Pre-Tax Income Historical Data
The historical data trend for Evoke Pharma's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Evoke Pharma's Pre-Tax Income
For the Drug Manufacturers - Specialty & Generic subindustry, Evoke Pharma's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evoke Pharma's Pre-Tax Income Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evoke Pharma's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Evoke Pharma's Pre-Tax Income falls into.
Evoke Pharma Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Evoke Pharma's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evoke Pharma (NAS:EVOK) Pre-Tax Income Explanation
Evoke Pharma's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as
During the past 13 years, Evoke Pharma's highest Pretax Margin was -71.33%. The lowest was -57195.65%. And the median was -427.74%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evoke Pharma Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Evoke Pharma's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EVOK has been successfully added to your 